| scholarly article | Q13442814 |
| P50 | author | John P Neoptolemos | Q39065464 |
| Eithne Costello | Q60596712 | ||
| William Greenhalf | Q89685245 | ||
| P2860 | cites work | Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 |
| Distant metastasis occurs late during the genetic evolution of pancreatic cancer | Q24624284 | ||
| The genetic basis for cancer treatment decisions | Q26849200 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. | Q27863396 | ||
| The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families | Q28266223 | ||
| Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer | Q28473944 | ||
| Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue | Q28730615 | ||
| Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer | Q29547558 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 | ||
| CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans | Q29614348 | ||
| EMT and dissemination precede pancreatic tumor formation | Q29615854 | ||
| The patterns and dynamics of genomic instability in metastatic pancreatic cancer | Q29618121 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| PARP inhibition: PARP1 and beyond | Q29619617 | ||
| Novel approaches to target pancreatic cancer | Q30318395 | ||
| Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial | Q30422810 | ||
| Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials | Q33398018 | ||
| MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. | Q33575825 | ||
| Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial | Q33686700 | ||
| Identification of serum proteins involved in pancreatic cancer cachexia | Q33752632 | ||
| Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development | Q33767883 | ||
| KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. | Q33858490 | ||
| Estimates of cancer incidence and mortality in Europe in 2008. | Q34095813 | ||
| Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? | Q34205171 | ||
| A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer | Q34546440 | ||
| Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial | Q34602771 | ||
| Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer | Q34613161 | ||
| Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial | Q34632818 | ||
| Biology and management of pancreatic cancer | Q34649019 | ||
| Use of archived specimens in evaluation of prognostic and predictive biomarkers | Q35007222 | ||
| MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma | Q35196518 | ||
| Deploying mouse models of pancreatic cancer for chemoprevention studies | Q35622126 | ||
| Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies | Q35787410 | ||
| Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma | Q35825974 | ||
| REporting recommendations for tumour MARKer prognostic studies (REMARK) | Q36615178 | ||
| Targeted agents in the treatment of pancreatic cancer: history and lessons learned | Q36839011 | ||
| Cancer-associated stromal fibroblasts promote pancreatic tumor progression | Q36844475 | ||
| nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer | Q36901035 | ||
| Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial | Q36910409 | ||
| The tumor microenvironment and its role in promoting tumor growth | Q36946019 | ||
| Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy | Q37127423 | ||
| Co-evolution of tumor cells and their microenvironment | Q37340741 | ||
| New treatment options for advanced pancreatic cancer | Q37345841 | ||
| The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. | Q37347966 | ||
| MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types | Q37641491 | ||
| Advanced pancreatic carcinoma: current treatment and future challenges | Q37681300 | ||
| Targeting Notch signaling in pancreatic cancer | Q37730861 | ||
| AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development | Q37760644 | ||
| Stromal biology and therapy in pancreatic cancer. | Q37802090 | ||
| Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. | Q37867362 | ||
| Notch signalling in solid tumours: a little bit of everything but not all the time | Q37867484 | ||
| Targeting the cancer initiating cell: the ultimate target for cancer therapy. | Q37990970 | ||
| Familial pancreatic cancer--current knowledge | Q38016055 | ||
| The role of stroma in pancreatic cancer: diagnostic and therapeutic implications | Q38019761 | ||
| Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial | Q38391782 | ||
| HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients | Q39844024 | ||
| Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma | Q39885220 | ||
| An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. | Q39940144 | ||
| The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. | Q40339631 | ||
| Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers | Q40354944 | ||
| Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice | Q40679145 | ||
| Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer | Q42147260 | ||
| A new approach to managing intraductal papillary mucinous pancreatic neoplasms | Q42409627 | ||
| K-ras mutations in pancreatic ductal proliferative lesions | Q42753837 | ||
| Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. | Q42914090 | ||
| Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma | Q42952825 | ||
| Cancer. Breaching the cancer fortress | Q43848667 | ||
| Improving outcome for patients with pancreatic cancer through centralization. | Q45112498 | ||
| Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma | Q46076287 | ||
| Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer | Q46643661 | ||
| Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result | Q46661406 | ||
| Development and characterization of gemcitabine-resistant pancreatic tumor cells. | Q46971449 | ||
| Pancreatic Cancer | Q54135367 | ||
| Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. | Q54327711 | ||
| New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy | Q56896222 | ||
| Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials | Q57693948 | ||
| Enhancing the translation of cancer biomarkers | Q60609565 | ||
| Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism | Q71542211 | ||
| Molecular detection of circulating cancer cells during surgery in patients with biliary-pancreatic cancer | Q78024546 | ||
| BRCA2 germline mutations in familial pancreatic carcinoma | Q78891021 | ||
| Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma | Q79600998 | ||
| Cancer cachexia | Q80142641 | ||
| Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups | Q81821222 | ||
| microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma | Q82678239 | ||
| Cancer stem cells: an evolving concept | Q83213559 | ||
| Understanding metastasis in pancreatic cancer: a call for new clinical approaches | Q83296482 | ||
| Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer | Q83916193 | ||
| c-Met is a marker of pancreatic cancer stem cells and therapeutic target | Q84816959 | ||
| The hedgehog pathway and pancreatic cancer | Q84925483 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| biomarker | Q864574 | ||
| P304 | page(s) | 435-444 | |
| P577 | publication date | 2012-06-26 | |
| P1433 | published in | Nature Reviews Gastroenterology & Hepatology | Q2108255 |
| P1476 | title | New biomarkers and targets in pancreatic cancer and their application to treatment | |
| P478 | volume | 9 |
| Q41448654 | 3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer |
| Q47315180 | A quantitative method for screening and identifying molecular targets for nanomedicine |
| Q37257883 | Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma |
| Q28533194 | Application of concave microwells to pancreatic tumor spheroids enabling anticancer drug evaluation in a clinically relevant drug resistance model |
| Q61814936 | B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma |
| Q38265405 | Biomarkers for early diagnosis of pancreatic cancer |
| Q34249344 | Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance |
| Q91976213 | Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer |
| Q26801191 | Circulating RNAs as new biomarkers for detecting pancreatic cancer |
| Q28073765 | Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer |
| Q52595056 | Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes. |
| Q34871953 | Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms |
| Q54979207 | Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma. |
| Q38941237 | Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. |
| Q35677885 | Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer. |
| Q47716584 | Contemporary Management of Localized Resectable Pancreatic Cancer |
| Q36889709 | Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer |
| Q89621149 | Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma |
| Q36763283 | Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus |
| Q33803923 | Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression |
| Q35095341 | Down-regulation of Gli transcription factor leads to the inhibition of migration and invasion of ovarian cancer cells via integrin β4-mediated FAK signaling |
| Q40756221 | Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy |
| Q37739809 | Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer. |
| Q37215557 | Elevated expression of CTHRC1 predicts unfavorable prognosis in patients with pancreatic ductal adenocarcinoma |
| Q26796523 | Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review) |
| Q52668506 | Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. |
| Q35552067 | GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma |
| Q49606173 | Genetics of pancreatic cancer and implications for therapy |
| Q58790645 | Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy |
| Q26774494 | Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer |
| Q36535127 | HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy |
| Q38862381 | High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC). |
| Q38468383 | Identification of circulating MicroRNAs as novel potential biomarkers for hepatocellular carcinoma detection: a systematic review and meta-analysis |
| Q38921259 | Identification of cystatin SN as a novel biomarker for pancreatic cancer |
| Q103038645 | Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer |
| Q41080828 | Inhibition of DNA2 nuclease as a therapeutic strategy targeting replication stress in cancer cells. |
| Q36654542 | Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. |
| Q35131201 | Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer |
| Q52663568 | Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. |
| Q48847725 | Knockdown of MicroRNA Let-7a Improves the Functionality of Bone Marrow-Derived Mesenchymal Stem Cells in Immunotherapy |
| Q49725736 | LITAF is a potential tumor suppressor in pancreatic cancer |
| Q37214680 | Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues |
| Q92978701 | Machine Learning and Network Analyses Reveal Disease Subtypes of Pancreatic Cancer and their Molecular Characteristics |
| Q89531299 | Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells |
| Q42154484 | Metabolomic biomarkers of pancreatic cancer: a meta-analysis study. |
| Q41769515 | MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer |
| Q37714165 | MicroRNA-7 functions as a tumor-suppressor gene by regulating ILF2 in pancreatic carcinoma |
| Q34093798 | MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer |
| Q42260827 | MicroRNAs for Detection of Pancreatic Neoplasia: Biomarker Discovery by Next-generation Sequencing and Validation in 2 Independent Cohorts |
| Q26765241 | Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer |
| Q34177065 | Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer |
| Q48106836 | Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. |
| Q38843622 | NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma |
| Q28082422 | New challenges in perioperative management of pancreatic cancer |
| Q37694882 | New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer |
| Q97420808 | Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients |
| Q38299502 | Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer |
| Q41858336 | PCMdb: pancreatic cancer methylation database. |
| Q89983732 | PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer |
| Q33801371 | Pancreatic biomarkers: could they be the answer? |
| Q44299542 | Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial |
| Q26801411 | Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma |
| Q37520294 | Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study |
| Q38773078 | Procathepsin E is highly abundant but minimally active in pancreatic ductal adenocarcinoma tumors |
| Q35963911 | Prognosis Relevance of Serum Cytokines in Pancreatic Cancer. |
| Q35149685 | Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer |
| Q38777938 | Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact |
| Q38753388 | RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis |
| Q89767256 | RNA cargos in extracellular vesicles derived from blood serum in pancreas associated conditions |
| Q47799174 | Reciprocal regulation of DGCR5 and miR-320a affects the cellular malignant phenotype and 5-FU response in pancreatic ductal adenocarcinoma |
| Q37708370 | Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis? |
| Q36983840 | Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1. |
| Q89475388 | Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer |
| Q53229089 | SOX9 regulates ERBB signalling in pancreatic cancer development. |
| Q33655712 | Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease |
| Q95841184 | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling |
| Q35795380 | Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation |
| Q39182251 | Targeting miR-21 for the therapy of pancreatic cancer |
| Q38878224 | The Interplay Between miR-148a and DNMT1 Might be Exploited for Pancreatic Cancer Therapy |
| Q48302587 | The Yonsei criteria as a clinically detectable parameter for excellent prognosis in resected left-sided pancreatic cancer: outcomes of a propensity score-matched analysis. |
| Q35820525 | The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival |
| Q50129161 | The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma. |
| Q91890975 | Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1 |
| Q28307924 | Transcriptional regulation of fibronectin by p21-activated kinase-1 modulates pancreatic tumorigenesis |
| Q48234356 | Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer |
| Q34067863 | Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts |
| Q34364766 | Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma |
| Q90529983 | Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages |
| Q88190147 | [Update of the S3 guidelines for pancreatic cancer. What is new for pathologists?] |
| Q30566337 | cAMP inhibits migration, ruffling and paxillin accumulation in focal adhesions of pancreatic ductal adenocarcinoma cells: effects of PKA and EPAC. |
| Q36857512 | iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance |
| Q58988424 | miRNAs for the Detection of MultiDrug Resistance: Overview and Perspectives |
Search more.